Loading...
Loading...
Vanda Pharmaceuticals Inc. (Vanda)
VNDA today announced that a favorable Markman ruling has been issued by the United States District Court for the District of Delaware in the patent infringement lawsuit filed by Vanda against Roxane Laboratories Inc. (Roxane) regarding Roxane's submission of an Abbreviated New Drug Application to make and sell a generic version of Fanapt®.
A Markman ruling, also known as a Claim Construction Ruling, is a court ruling in which the judge determines the meaning of key terms from certain disputed patent claims. The Delaware court, which was asked to construe disputed patent claim terms in U.S. Patent number 8,586,610 ('610), rejected Roxane's proposed construction of all the disputed claim terms. The '610 patent is expected to expire in November 2027.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in